Dr. Tudor Ilca

Dr. Tudor Ilca has a degree in biochemistry from the University of Bremen in Germany and a PhD in immunology from the Cambridge University on the potential therapeutic role of TABPR chaperone proteins in loading immunogenic peptides directly onto HLA class I molecules present on the surface of tumour cells and has described this process. In addition, he performed activation and neutralization tests using primary CD8+ T cells to validate the potential application of TAPBPR as an immunomodulator.

Tudor Ilca is currently working as a principal researcher at Mabylon, a biotech start-up in Zurich, where he is developing and characterising monoclonal and multispecific antibodies against a wide range of allergens as well as against proteins that contribute to the triggering of certain neurodegenerative diseases.